Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications

Rheumatoid arthritis is an autoimmune disease that exhibits significant clinical heterogeneity. There are various treatments for rheumatoid arthritis, including disease-modifying anti-rheumatic drugs (DMARDs), glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and inflammatory cytokine...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianan Zhao, Shicheng Guo, Steven J. Schrodi, Dongyi He
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	rheumatoid arthritis heterogeneity pathophysiology interaction genetics mechanism Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/1d9be0209f0246b68da5a479a432aaf9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d9be0209f0246b68da5a479a432aaf9
record_format	dspace
spelling	oai:doaj.org-article:1d9be0209f0246b68da5a479a432aaf92021-12-01T02:33:18ZMolecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications1664-322410.3389/fimmu.2021.790122https://doaj.org/article/1d9be0209f0246b68da5a479a432aaf92021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.790122/fullhttps://doaj.org/toc/1664-3224Rheumatoid arthritis is an autoimmune disease that exhibits significant clinical heterogeneity. There are various treatments for rheumatoid arthritis, including disease-modifying anti-rheumatic drugs (DMARDs), glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and inflammatory cytokine inhibitors (ICI), typically associated with differentiated clinical effects and characteristics. Personalized responsiveness is observed to the standard treatment due to the pathophysiological heterogeneity in rheumatoid arthritis, resulting in an overall poor prognosis. Understanding the role of individual variation in cellular and molecular mechanisms related to rheumatoid arthritis will considerably improve clinical care and patient outcomes. In this review, we discuss the source of pathophysiological heterogeneity derived from genetic, molecular, and cellular heterogeneity and their possible impact on precision medicine and personalized treatment of rheumatoid arthritis. We provide emphasized description of the heterogeneity derived from mast cells, monocyte cell, macrophage fibroblast-like synoviocytes and, interactions within immune cells and with inflammatory cytokines, as well as the potential as a new therapeutic target to develop a novel treatment approach. Finally, we summarize the latest clinical trials of treatment options for rheumatoid arthritis and provide a suggestive framework for implementing preclinical and clinical experimental results into clinical practice.Jianan ZhaoJianan ZhaoShicheng GuoShicheng GuoSteven J. SchrodiSteven J. SchrodiDongyi HeDongyi HeDongyi HeFrontiers Media S.A.articlerheumatoid arthritisheterogeneitypathophysiologyinteractiongeneticsmechanismImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis heterogeneity pathophysiology interaction genetics mechanism Immunologic diseases. Allergy RC581-607
spellingShingle	rheumatoid arthritis heterogeneity pathophysiology interaction genetics mechanism Immunologic diseases. Allergy RC581-607 Jianan Zhao Jianan Zhao Shicheng Guo Shicheng Guo Steven J. Schrodi Steven J. Schrodi Dongyi He Dongyi He Dongyi He Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
description	Rheumatoid arthritis is an autoimmune disease that exhibits significant clinical heterogeneity. There are various treatments for rheumatoid arthritis, including disease-modifying anti-rheumatic drugs (DMARDs), glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), and inflammatory cytokine inhibitors (ICI), typically associated with differentiated clinical effects and characteristics. Personalized responsiveness is observed to the standard treatment due to the pathophysiological heterogeneity in rheumatoid arthritis, resulting in an overall poor prognosis. Understanding the role of individual variation in cellular and molecular mechanisms related to rheumatoid arthritis will considerably improve clinical care and patient outcomes. In this review, we discuss the source of pathophysiological heterogeneity derived from genetic, molecular, and cellular heterogeneity and their possible impact on precision medicine and personalized treatment of rheumatoid arthritis. We provide emphasized description of the heterogeneity derived from mast cells, monocyte cell, macrophage fibroblast-like synoviocytes and, interactions within immune cells and with inflammatory cytokines, as well as the potential as a new therapeutic target to develop a novel treatment approach. Finally, we summarize the latest clinical trials of treatment options for rheumatoid arthritis and provide a suggestive framework for implementing preclinical and clinical experimental results into clinical practice.
format	article
author	Jianan Zhao Jianan Zhao Shicheng Guo Shicheng Guo Steven J. Schrodi Steven J. Schrodi Dongyi He Dongyi He Dongyi He
author_facet	Jianan Zhao Jianan Zhao Shicheng Guo Shicheng Guo Steven J. Schrodi Steven J. Schrodi Dongyi He Dongyi He Dongyi He
author_sort	Jianan Zhao
title	Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
title_short	Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
title_full	Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
title_fullStr	Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
title_full_unstemmed	Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
title_sort	molecular and cellular heterogeneity in rheumatoid arthritis: mechanisms and clinical implications
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1d9be0209f0246b68da5a479a432aaf9
work_keys_str_mv	AT jiananzhao molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT jiananzhao molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT shichengguo molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT shichengguo molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT stevenjschrodi molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT stevenjschrodi molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT dongyihe molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT dongyihe molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications AT dongyihe molecularandcellularheterogeneityinrheumatoidarthritismechanismsandclinicalimplications
_version_	1718405889766981632

Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications

Ejemplares similares